GAGulce Askin

Gulce Askin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gulce Askin has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States

    by Amanda M. Kong, Jacqueline Lucia, Mary J. Christoph, Uche Mordi, Daisha Joseph, Gulce Askin, Daniela Yucuma, Neia Prata Menezes, Peter McMahon, Travis Lim

    Background Persistence and adherence to antiretroviral therapy (ART) are crucial for effective viral suppression and may be impacted by comorbidities and polypharmacy in older people with HIV (PWH). This study compared ART persistence among treatment-naive and treatment-experienced PWH aged ≥50 years who received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG)-based regimens. Methods This observational, retrospective study utilized US medical and pharmacy claims data from HealthVerity Marketplace (1 January 2015 to 29 February 2024). PWH were aged ≥50 years and received B/F/TAF, dolutegravir/lamivudine (DTG/3TC), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), or DTG-based multitablet regimens (MTRs). Baseline characteristics were balanced using inverse probability of treatment weighting. Time to nonpersistence (i.e., discontinuation or switching) was depicted using Kaplan–Meier plots. Risk of nonpersistence was modeled using weighted Cox proportional hazards models. Results Overall, 32,448 PWH aged ≥50 years were included in the analysis; 77% were treatment experienced. Among treatment-experienced PWH, those who received B/F/TAF had significantly lower adherence during the baseline period than those who received DTG/3TC and significantly higher adherence during the baseline period than those who received DTG/ABC/3TC and DTG-based MTRs. Nonetheless, persistence on B/F/TAF was longer than DTG/ABC/3TC and DTG-based MTRs in both subgroups. Treatment-naive and treatment-experienced PWH who received B/F/TAF had significantly lower hazards of nonpersistence versus those who received DTG/ABC/3TC and DTG-based MTRs (all p < 0.001), as did treatment-naive PWH who received B/F/TAF versus DTG/3TC (p = 0.031). Conclusions B/F/TAF was associated with higher persistence than other ART regimens among older PWH. Findings underscore the importance of tailored ART selection to address the unique challenges faced by older PWH.

  • A Longitudinal Analysis of Early Lesion Growth in Presymptomatic Patients with Cerebral Adrenoleukodystrophy

    by E.J. Mallack, G. Askin, S. van de Stadt, P.A. Caruso, P.L. Musolino, M. Engelen, S.N. Niogi, F.S. Eichler

    BACKGROUND AND PURPOSE: Cerebral adrenoleukodystrophy is a devastating neurological disorder caused by mutations in the ABCD1 gene. Our aim was to model and compare the growth of early cerebral lesions from longitudinal MRIs obtained in presymptomatic patients with progressive and arrested cerebral adrenoleukodystrophy using quantitative MR imaging–based lesion volumetry. MATERIALS AND METHODS: We retrospectively quantified and modeled the longitudinal growth of early cerebral lesions from 174 MRIs obtained from 36 presymptomatic male patients with cerebral adrenoleukodystrophy. Lesions were manually segmented using subject-specific lesion-intensity thresholding. Volumes were calculated and plotted across time. Lesion velocity and acceleration were calculated between sequentially paired and triplet MRIs, respectively. Linear mixed-effects models were used to assess differences in growth parameters between progressive and arrested phenotypes. RESULTS: The median patient age was 7.4 years (range, 3.9–37.0 years). Early-stage cerebral disease progression was inversely correlated with age (ρ = −0.6631, P < .001), early lesions can grow while appearing radiographically stable, lesions undergo sustained acceleration in progressive cerebral adrenoleukodystrophy (β = 0.10 mL/month2 [95% CI, 0.05−0.14 mL/month2], P < .001), and growth trajectories diverge between phenotypes in the presymptomatic time period. CONCLUSIONS: Measuring the volumetric changes in newly developing cerebral lesions across time can distinguish cerebral adrenoleukodystrophy phenotypes before symptom onset. When factored into the overall clinical presentation of a patient with a new brain lesion, quantitative MR imaging–based lesion volumetry may aid in the accurate prediction of patients eligible for therapy.


  • Joint periviability counseling between neonatology and obstetrics is a rare occurrence

    by Rachel Reed, Tracy Grossman, Gulce Askin, Linda M. Gerber, Ericalyn Kasdorf

    Objective To investigate the frequency with which neonatal and maternal–fetal medicine (MFM) providers perform joint periviability counseling (JPC), compare content of counseling, and identify perceived barriers to JPC. Study design An anonymous REDCap survey was e-mailed to members of the American Academy of Pediatrics Section on Neonatal-Perinatal Medicine and to members of the Society for MFM. Results There were 424 neonatal and 115 MFM participants. Fifty-two percent of neonatal and 35% of MFM respondents reported rarely/never performing JPC (p < 0.001), while 80% and 82%, respectively felt it would improve counseling. Content of counseling was similar, except for length of stay with 93% of neonatal vs. 85% of MFM respondents addressing this (p = 0.03). The majority (>60%) of respondents in both groups reported that clinical duties posed a significant/great barrier to JPC. Conclusion JPC is recommended but infrequently performed, with both specialties interested in further collaboration to strengthen the counseling provided.


  • Spleen phenotype in autosomal dominant polycystic kidney disease

    by X. Yin, W.K. Prince, J.D. Blumenfeld, W. Zhang, S. Donahue, W.O. Bobb, H. Rennert, G. Askin, I. Barash, M.R. Prince


  • Open Access

    The Use of Noncontrast Quantitative MRI to Detect Gadolinium-Enhancing Multiple Sclerosis Brain Lesions: A Systematic Review and Meta-Analysis

    by A. Gupta, K. Al-Dasuqi, F. Xia, G. Askin, Y. Zhao, D. Delgado, Y. Wang

    BACKGROUND: Concerns have arisen about the long-term health effects of repeat gadolinium injections in patients with multiple sclerosis and the incomplete characterization of MS lesion pathophysiology that results from relying on enhancement characteristics alone. PURPOSE: Our aim was to perform a systematic review and meta-analysis analyzing whether noncontrast MR imaging biomarkers can distinguish enhancing and nonenhancing brain MS lesions. DATA SOURCES: Our sources were Ovid MEDLINE, Ovid Embase, and the Cochrane data base from inception to August 2016. STUDY SELECTION: We included 37 journal articles on 985 patients with MS who had MR imaging in which T1-weighted postcontrast sequences were compared with noncontrast sequences obtained during the same MR imaging examination by using ROI analysis of individual MS lesions. DATA ANALYSIS: We performed random-effects meta-analyses comparing the standard mean difference of each MR imaging metric taken from enhancing-versus-nonenhancing lesions. DATA SYNTHESIS: DTI-based fractional anisotropy values are significantly different between enhancing and nonenhancing lesions (P = .02), with enhancing lesions showing decreased fractional anisotropy compared with nonenhancing lesions. Of the other most frequently studied MR imaging biomarkers (mean diffusivity, magnetization transfer ratio, or ADC), none were significantly different (P values of 0.30, 0.47, and 0.19. respectively) between enhancing and nonenhancing lesions. Of the limited studies providing diagnostic accuracy measures, gradient-echo-based quantitative susceptibility mapping had the best performance in discriminating enhancing and nonenhancing MS lesions. LIMITATIONS: MR imaging techniques and patient characteristics were variable across studies. Most studies did not provide diagnostic accuracy measures. All imaging metrics were not studied in all 37 studies. CONCLUSIONS: Noncontrast MR imaging techniques, such as DTI-based FA, can assess MS lesion acuity without gadolinium.


  • Open Access

    Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation

    by Y. Zhang, S.A. Gauthier, A. Gupta, W. Chen, J. Comunale, G.C.-Y. Chiang, D. Zhou, G. Askin, W. Zhu, D. Pitt, et al.

    BACKGROUND AND PURPOSE: Quantitative susceptibility mapping and R2* are sensitive to myelin and iron changes in multiple sclerosis lesions. This study was designed to characterize lesion changes on quantitative susceptibility mapping and R2* at various gadolinium-enhancement stages. MATERIALS AND METHODS: This study included 64 patients with MS with different enhancing patterns in white matter lesions: nodular, shell-like, nonenhancing < 1 year old, and nonenhancing 1–3 years old. These represent acute, late acute, early chronic, and late chronic lesions, respectively. Susceptibility values measured on quantitative susceptibility mapping and R2* values were compared among the 4 lesion types. Their differences were assessed with a generalized estimating equation, controlling for Expanded Disability Status Scale score, age, and disease duration. RESULTS: We analyzed 203 lesions: 80 were nodular-enhancing, of which 77 (96.2%) were isointense on quantitative susceptibility mapping; 33 were shell-enhancing, of which 30 (90.9%) were hyperintense on quantitative susceptibility mapping; and 49 were nonenhancing lesions < 1 year old and 41 were nonenhancing lesions 1–3 years old, all of which were hyperintense on quantitative susceptibility mapping. Their relative susceptibility/R2* values were 0.5 ± 4.4 parts per billion/−5.6 ± 2.9 Hz, 10.2 ± 5.4 parts per billion/−8.0 ± 2.6 Hz, 20.2 ± 7.8 parts per billion/−3.1 ± 2.3 Hz, and 33.2 ± 8.2 parts per billion/−2.0 ± 2.6 Hz, respectively, and were significantly different (P < .005). CONCLUSIONS: Early active MS lesions with nodular enhancement show R2* decrease but no quantitative susceptibility mapping change, reflecting myelin breakdown; late active lesions with peripheral enhancement show R2* decrease and quantitative susceptibility mapping increase in the lesion center, reflecting further degradation and removal of myelin debris; and early or late chronic nonenhancing lesions show both quantitative susceptibility mapping and R2* increase, reflecting iron accumulation.